Skip to main content

Table 2 Demographic, current disease status, pulmonary involvement, treatment, and the cytokines serum levels of the patients with antisynthetase syndrome. Laboratory profiles of the control group

From: High YKL-40 serum levels and its expression in the muscle tissues of patients with antisynthetase syndrome

 

ASSD

(n = 64)

Control

(n = 64)

P

IMACS set scores

 MMT-8 (0–80)

78 (71–80)

 

 Patient’ VAS (0–10)

4.0 (2.0–6.0)

 

 Physician’ VAS (0–10)

3.0 (0.0–5.0)

 

 MYOACT (0–60)

4.0 (0.5–2.5)

 

 HAQ (0.00–3.00)

0.67 (0.13–1.38)

 

 CPK (U/L)

208 (98–597)

106 (78–161)

< 0.001

 LDH (U/L)

352 (243–590)

346 (312–345)

0.937

 AST (U/L)

24 (17–37)

20 (16–23)

0.009

 ALT (U/L)

24 (16–57)

18 (13–25)

0.030

Lung involvements

 Ground-glass

46 (71.9)

 

 Incipient pneumopathy

40 (62.5)

 

 Pulmonary fibrosis

14 (21.9)

 

 Pulmonary nodules

11 (17.2)

 

 FVC (% predict), n = 39

62.5 (48.0–73.5)

 

 FEV1 (% predicted), n = 39

64 (49–77)

 

 FEV1/FVC ratio, n = 39

0.90 (0.93–1.08)

 

 DLCO2 (% predicted), n = 39

61.0 (37.8–73.0)

 

Treatment

 Prednisone

  Current use

46 (71.9)

 

  Dose (mg/day)

10 (0–40)

 

 Immunosuppressive drugs

47 (73.4)

 

  Azathioprine

23 (35.9)

 

  Mycophenolate mofetil

11 (17.2)

 

  Methotrexate

14 (21.9)

 

  Antimalarial

4 (6.3)

 

  Leflunomide

2 (3.1)

 

  Cyclosporine

3 (4.7)

 

  Cyclophosphamide

1 (1.7)

 

 Rituximab

16 (25.0)

 

Cytokines

 YKL-40 (pg/mL)

538.4 (363.4–853.1)

270.0 (201.8–451.9)

< 0.001

 IFNγ (pg/mL)

0.02 (0.00–1.89)

0.02 (0.00–0.17)

0.876

 TNFα (pg/mL)

48.4 (31.0–66.3)

39.6 (29.3–49.0)

0.011

  1. Data are expressed as mean ± standard deviation (SD); median (interquartile 25th - 75th) or frequency (%)
  2. ALT alanine aminotransferase; ASSD antisynthetase syndrome; AST aspartate aminotransferase; CPK creatine phosphokinase; DLCO2 diffusion of carbon dioxide; FEV1 forced expiratory volume in one second; FVC forced vital capacity; HAQ Health Assessment Questionnaire; IFN interferon; IMACS: International Myositis Assessment and Clinical Studies Group; LDH lactate dehydrogenase; MMT-8 Manual Muscle Testing; MYOACT Myositis Disease Activity Assessment Visual Analogue Scales; TNF tumor necrosis factor; VAS Visual Analog Scale; YKL chitinase-3-like-1 protein